The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Shares in Anglo-Swedish pharma major AstraZeneca jumped up by more than 3% on Friday after the presentation of Phase III results of a combination involving Lynparza (olaparib) in prostate cancer. 24 September 2021
Shares of US oncology specialist Nektar Therapeutics rose 5% to $17.10, after it announced a deal with two pharma majors to trial its investigational interleukin-15 (IL-15) receptor agonist NKTR-255. 24 September 2021
Pharmsynthez, one of Russia’s leading drugmakers, is planning to launch one of the largest productions of hormonal preparations in Russia, which will be located the city of Tyumen by November of the current year. 24 September 2021
Spanish drugmaker PharmaMar has announced its licensing partner, Specialised Therapeutics Asia (STA), has received provisional marketing approval for Zepzelca (lurbinectedin) by the Singapore Health Sciences Authority (HSA) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) who have progressed after prior platinum-containing chemotherapy. 24 September 2021
Japan’s Kyowa Kirin has provided new data for Crysvita (burosumab), revealing benefits for people with the rare metabolic bone disorder X-linked hypophosphatemia (XLH). 24 September 2021
Swiss pharma giant Roche today announced data from across its growing neuromuscular portfolio at the World Muscle Society (WMS) Virtual Congress 20–24 September 2021. 24 September 2021
Otsuka Pharmaceutical company Astex Pharmaceuticals has provided new Phase III data from the ASCERTAIN trial of Inqovi (decitabine/cedazuridine). 24 September 2021
R-Pharm, one of Russia’s leading drugmakers, has started the production of a vaccine against COVID-19 under a license from Oxford University and UK pharma major AstraZeneca, according to recent statements made by some Russian state officials and local media reports. 24 September 2021
The aim of the US Food and Drug Administration’s Accelerated Approval Program (AAP) is to expedite the development of new therapies that address an unmet need in the treatment of serious diseases.1 However, recent controversies regarding AAP drugs have brought the program under severe scrutiny. We discuss the pros and cons of the program and how they impact its future. 24 September 2021
UK biotech Immunocore Holdings has announced that data from a Phase III trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma (mUM) has been published in The New England Journal of Medicine (NEJM). 23 September 2021
The World Health Organization's Director General Tedros Adhanom Ghebreyesus has thanked India's Minister Mansukh Mandaviya for announcing that India will resume crucial COVID-19 vaccine shipments to COVAX in October. 23 September 2021
US biotech Novavax and its partner the Serum Institute of India today announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant. 23 September 2021
China’s Worg Pharmaceuticals (Hangzhou) has entered into an asset purchase agreement to acquire Belgian biotech’s Apitope International’s proprietary platform and therapeutic pipeline. 23 September 2021
Incyte Corp’s shares were down as much as 8.5% at $69.59 yesterday, despite the company receiving regulatory approval for a second drug within two days. 23 September 2021
Boston, USA-based Rhythm Pharmaceuticals has presented new data and analyses from Phase II and III trials of its candidate setmelanotide. 23 September 2021
Anglo-Swedish pharma major AstraZeneca has reached an agreement to collaborate with VaxEquity for the discovery, development and commercialization of the proprietary self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London. 23 September 2021
The HER2+ breast cancer market is expected to experience low growth from $10.4 billion in 2020 to $12.1 billion in 2030 across the eight major markets (8MM: the USA, France, Germany, Italy, Spain, UK, China and Japan) at a compound annual growth rate (CAGR) of 1.5%. 23 September 2021
US biotech Gilead Sciences (Nasdaq: GILD) has released positive results from a Phase III randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury (remdesivir) for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. 23 September 2021